The specific role of O⁶-methylguanine-DNA methyltransferase inhibitors in cancer chemotherapy

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Lawley PD. Alkylation of DNA and its aftermath. Bioessays 17(6), 561–568 (1995).
  Medline CASGoogle Scholar
• 2 Sun GH, Zhao LJ, Zhong RG. The induction and repair of DNA interstrand crosslinks and implications in cancer chemotherapy. Anticancer Agents Med. Chem. 16(2), 221–246 (2016).
  CASGoogle Scholar
• 3 Sun GH, Fan TJ, Zhao LJ et al. The potential of combi-molecules with DNA-damaging function as anticancer agents. Future Med. Chem. 9(4), 403–435 (2017).
  CASGoogle Scholar
• 4 Kaina B, Margison GP, Christmann M. Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell. Mol. Life Sci. 67(21), 3663–3681 (2010). •• An excellent review that described the DNA alkylating agents widely used in clinic, expression of MGMT in different tissues, MGMT-mediated resistance and its potential inhibitors in clinical studies.
  Medline CASGoogle Scholar
• 5 Sun GH, Zhao LJ, Fan TJ et al. Investigations on the effect of O⁶-benzylguanine on the formation of dG-dC interstrand cross-links induced by chloroethylnitrosoureas in human glioma cells using stable isotope dilution high-performance liquid chromatography electrospray ionization tandem mass spectrometry. Chem. Res. Toxicol. 27(7), 1253–1262 (2014).
  Medline CASGoogle Scholar
• 6 Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 332(2), 237–248 (2013).
  Medline CASGoogle Scholar
• 7 Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu. Rev. Med. 66, 129–143 (2015).
  Medline CASGoogle Scholar
• 8 Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 4(4), 296–307 (2004).
  Medline CASGoogle Scholar
• 9 Zhao LJ, Ma XY, Zhong RG. A density functional theory investigation on the formation mechanisms of DNA interstrand crosslinks induced by chloroethylnitrosoureas. Int. J. Quantum Chem. 113(9), 1299–1306 (2013).
  CASGoogle Scholar
• 10 Zhao LJ, Ma XY, Zhong RG. Comparative theoretical investigation of the formation of DNA interstrand crosslinks induced by two kinds of N-nitroso compounds: nitrosoureas and nitrosamines. J. Phys. Org. Chem. 25(12), 1153–1167 (2012).
  CASGoogle Scholar
• 11 Bai BQ, Zhao LJ, Zhong RG. Quantification of meCCNU-induced dG-dC crosslinks in oligonucleotide duplexes by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 25(14), 2027–2034 (2011).
  Medline CASGoogle Scholar
• 12 Zhao LJ, Li LL, Xu J et al. Comparative investigation of the DNA inter-strand crosslinks induced by ACNU, BCNU, CCNU and FTMS using high-performance liquid chromatography–electrospray ionization tandem mass spectrometry. Int. J. Mass Spectrom. 368, 30–36 (2014).
  CASGoogle Scholar
• 13 Pegg AE. Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools. Chem. Res. Toxicol. 24(5), 618–639 (2011).
  Medline CASGoogle Scholar
• 14 Belanich M, Pastor M, Randall T et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 56(4), 783–788 (1996).
  Medline CASGoogle Scholar
• 15 Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 20(9), 2388–2399 (2002).
  Medline CASGoogle Scholar
• 16 Bodell WJ. DNA alkylation products formed by 1-(2-chloroethyl)-1-nitrosourea as molecular dosimeters of therapeutic response. J. Neurooncol. 91(3), 257–264 (2009).
  Medline CASGoogle Scholar
• 17 Tubbs JL, Pegg AE, Tainer JA. DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O⁶-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy. DNA Repair 6(8), 1100–1115 (2007).
  Medline CASGoogle Scholar
• 18 Rydberg B, Spurr N, Karran P. cDNA cloning and chromosomal assignment of the human O⁶-methylguanine-DNA methyltransferase – cDNA expression in Escherichia coli and gene expression in human cells. J. Biol. Chem. 265(16), 9563–9569 (1990).
  Medline CASGoogle Scholar
• 19 Hayakawa H, Koike G, Sekiguchi M. Expression and cloning of complementary-DNA for a human enzyme that repairs O⁶-methylguanine in DNA. J. Mol. Biol. 213(4), 739–747 (1990).
  Medline CASGoogle Scholar
• 20 Tano K, Shiota S, Collier J et al. Isolation and structural characterization of a cDNA clone encoding the human DNA-repair protein for O⁶-alkylguanine. Proc. Natl Acad. Sci. USA 87(2), 686–690 (1990).
  Medline CASGoogle Scholar
• 21 Daniels DS, Mol CD, Arvai AS et al. Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding. EMBO J. 19(7), 1719–1730 (2000).
  Medline CASGoogle Scholar
• 22 Daniels DS, Tainer JA. Conserved structural motifs governing the stoichiometric repair of alkylated DNA by O⁶-alkylguanine-DNA alkyltransferase. Mutat. Res. 460(3–4), 151–163 (2000).
  Medline CASGoogle Scholar
• 23 Daniels DS, Woo TT, Luu KX et al. DNA binding and nucleotide flipping by the human DNA repair protein AGT. Nat. Struct. Mol. Biol. 11(8), 714–720 (2004). • A critical investigation on the crystal structure of MGMT and the mechanism of action of MGMT-mediated repair of O6-alkylguanines.
  Medline CASGoogle Scholar
• 24 Srivenugopal KS, Yuan XH, Friedman HS et al. Ubiquitination-dependent proteolysis of O⁶-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O⁶-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry 35(4), 1328–1334 (1996).
  Medline CASGoogle Scholar
• 25 Xu-Welliver M, Pegg AE. Degradation of the alkylated form of the DNA repair protein, O⁶-alkylguanine-DNA alkyltransferase. Carcinogenesis 23(5), 823–830 (2002).
  Medline CASGoogle Scholar
• 26 Mostofa AGM, Punganuru SR, Madala HR et al. S-phase specific downregulation of human O⁶-methylguanine DNA methyltransferase (MGMT) and its serendipitous interactions with PCNA and p21^cip1 proteins in glioma cells. Neoplasia 20(4), 305–323 (2018).
  Medline CASGoogle Scholar
• 27 Philip S, Swaminathan S, Kuznetsov SG et al. Degradation of BRCA2 in alkyltransferase-mediated DNA repair and its clinical implications. Cancer Res. 68(23), 9973–9981 (2008).
  Medline CASGoogle Scholar
• 28 Futscher BW, Micetich KC, Barnes DM et al. Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells. Cancer Commun. 1(1), 65–73 (1989).
  Medline CASGoogle Scholar
• 29 Micetich KC, Futscher B, Koch D et al. Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer. J. Natl Cancer Inst. 84(4), 256–261 (1992).
  Medline CASGoogle Scholar
• 30 Panella TJ, Smith DC, Schold SC et al. Modulation of O⁶-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin – a Phase I trial. Cancer Res. 52(9), 2456–2459 (1992).
  Medline CASGoogle Scholar
• 31 Smith DC, Gerson SL, Liu LL et al. Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O⁶-alkylguanine-DNA-alkyltransferase. Clin. Cancer Res. 2(7), 1129–1134 (1996).
  Medline CASGoogle Scholar
• 32 Lee SM, Margison GP, Woodcock A, Thatcher N. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br. J. Cancer 67(6), 1356–1360 (1993).
  Medline CASGoogle Scholar
• 33 Gander M, Leyvraz S, Decosterd L et al. Sequential administration of temozolomide and fotemustine: depletion of O⁶-alkyguanineDNA alkyltransferase in blood lymphocytes and in tumours. Ann. Oncol. 10(7), 831–838 (1999).
  Medline CASGoogle Scholar
• 34 Dolan ME, Pegg AE, Hora NK, Erickson LC. Effect of O⁶-methylguanine on DNA interstrand cross-link formation by chloroethylnitrosoureas and 2-chloroethyl(methylsulfonyl)methanesulfonate. Cancer Res. 48(13), 3603–3606 (1988).
  Medline CASGoogle Scholar
• 35 Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O⁶-alkylguanine-DNA alkyltransferase activity by O⁶-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl Acad. Sci. USA 87(14), 5368–5372 (1990). • An important study to evaluate the ability of O6-BG to deplete MGMT in vitro and in vivo and the effect of O6-BG to sensitize tumor cells to killing of guanine O6-alkylating agents.
  Medline CASGoogle Scholar
• 36 Dolan ME, Morimoto K, Pegg AE. Reduction of O⁶-alkylguanine-DNA alkyltransferase activity in HeLa cells treated with O⁶-alkylguanines. Cancer Res. 45(12), 6413–6417 (1985).
  Medline CASGoogle Scholar
• 37 Dolan ME, Mitchell RB, Mummert C et al. Effect of O⁶-benzylguanine analogs on sensitivity of human tumor cells to the cytotoxic effects of alkylating-agents. Cancer Res. 51(13), 3367–3372 (1991).
  Medline CASGoogle Scholar
• 38 Friedman HS, Keir S, Pegg AE et al. O⁶-benzylguanine-mediated enhancement of chemotherapy. Mol. Cancer Ther. 1(11), 943–948 (2002).
  Medline CASGoogle Scholar
• 39 Moschel RC, McDougall MG, Dolan ME et al. Structural features of substituted purine derivatives compatible with depletion of human O⁶-alkylguanine-DNA alkyltransferase. J. Med. Chem. 35(23), 4486–4491 (1992).
  Medline CASGoogle Scholar
• 40 Chae MY, McDougall MG, Dolan ME et al. Substituted O⁶-benzylguanine derivatives and their inactivation of human O-6-alkylguanine-DNA alkyltransferase. J. Med. Chem. 37(3), 342–347 (1994).
  Medline CASGoogle Scholar
• 41 Chae MY, Swenn K, Kanugula S et al. 8-Substituted O⁶-benzylguanine, substituted 6(4)-(benzyloxy)pyrimidine, and related derivatives as inactivators of human O⁶-alkylguanine-DNA alkyltransferase. J. Med. Chem. 38(2), 359–365 (1995).
  Medline CASGoogle Scholar
• 42 McElhinney RS, Donnelly DJ, McCormick JE et al. Inactivation of O⁶-alkylguanine-DNA alkyltransferase. 1. Novel O⁶-(hetarylmethyl)guanines having basic rings in the side chain. J. Med. Chem. 41(26), 5265–5271 (1998).
  Medline CASGoogle Scholar
• 43 Griffin RJ, Arris CE, Bleasdale C et al. Resistance-modifying agents. 8. Inhibition of O⁶-alkylguanine-DNA alkyltransferase by O⁶-alkenyl-, O⁶-cycloalkenyl-, and O⁶-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O⁶-(1-cyclopentenylmethyl)guanine. J. Med. Chem. 43(22), 4071–4083 (2000).
  Medline CASGoogle Scholar
• 44 Pauly GT, Loktionova NA, Fang QM et al. Substitution of aminomethyl at the meta-position enhances the inactivation of O⁶-alkylguanine-DNA alkyltransferase by O⁶-benzylguanine. J. Med. Chem. 51(22), 7144–7153 (2008).
  Medline CASGoogle Scholar
• 45 Sun GH, Fan TJ, Zhang N et al. Identification of the structural features of guanine derivatives as MGMT inhibitors using 3D-QSAR modeling combined with molecular docking. Molecules 21(7), 823 (2016). • An interesting investigation that provided an insight into the understanding of the structure–activity relationship of guanine derivatives as MGMT inhibitors and gave useful information for designing novel MGMT inhibitors with desired activity.
  Google Scholar
• 46 Sun GH, Zhang N, Zhao LJ et al. Synthesis and antitumor activity evaluation of a novel combi-nitrosourea prodrug: designed to release a DNA cross-linking agent and an inhibitor of O⁶-alkylguanine-DNA alkyltransferase. Bioorg. Med. Chem. 24(9), 2097–2107 (2016).
  Medline CASGoogle Scholar
• 47 Wang YM, Ren T, Lai XX et al. Synthesis and antitumor activity evaluation of a novel combinitrosourea prodrug: BGCNU. ACS Med. Chem. Lett. 8(2), 174–178 (2017).
  MedlineGoogle Scholar
• 48 Terashima I, Kohda K. Inhibition of human O⁶-alkylguanine-DNA alkyltransferase and potentiation of the cytotoxicity of chloroethylnitrosourea by 4(6)-(benzyloxy)-2,6(4)-diamino-5-(nitro or nitroso)pyrimidine derivatives and analogues. J. Med. Chem. 41(4), 503–508 (1998).
  Medline CASGoogle Scholar
• 49 Adams CA, Melikishvili M, Rodgers DW et al. Topologies of complexes containing O⁶-alkylguanine-DNA alkyltransferase and DNA. J. Mol. Biol. 389(2), 248–263 (2009).
  Medline CASGoogle Scholar
• 50 Lopez S, Margison GP, McElhinney RS et al. Towards more specific O⁶-methylguanine-DNA methyltransferase (MGMT) inactivators. Bioorg. Med. Chem. 19(5), 1658–1665 (2011).
  Medline CASGoogle Scholar
• 51 Ruiz FM, Gil-Redondo R, Morreale A et al. Structure-based discovery of novel non-nucleosidic DNA alkyltransferase inhibitors: virtual screening and in vitro and in vivo activities. J. Chem. Inf. Model. 48(4), 844–854 (2008).
  Medline CASGoogle Scholar
• 52 Melikishvili M, Rodgers DW, Fried MG. 6-Carboxyfluorescein and structurally similar molecules inhibit DNA binding and repair by O⁶-alkylguanine DNA alkyltransferase. DNA Repair 10(12), 1193–1202 (2011).
  Medline CASGoogle Scholar
• 53 Wang C, Abegg D, Hoch DG et al. Chemoproteomics-enabled discovery of a potent and selective inhibitor of the DNA repair protein MGMT. Angew. Chem. Int. Ed. Engl. 55(8), 2911–2915 (2016).
  Medline CASGoogle Scholar
• 54 Laval F, Wink DA. Inhibition by nitric oxide of the repair protein, O⁶-methylguanine-DNA-methyltransferase. Carcinogenesis 15(3), 443–447 (1994).
  Medline CASGoogle Scholar
• 55 Liu LP, Xu-Welliver M, Kanugula S et al. Inactivation and degradation of O⁶-alkylguanine-DNA alkyltransferase after reaction with nitric oxide. Cancer Res. 62(11), 3037–3043 (2002).
  Medline CASGoogle Scholar
• 56 Srivenugopal KS, Paranjpe A. The NO-releasing aspirin inactivates and degrades human MGMT more efficiently than O⁶-benzylguanine and greatly sensitizes brain tumor cells to alkylating agents. Proc. Am. Assoc. Cancer Res. 54, 1094 (2013).
  Google Scholar
• 57 Chen WN, Xiao Z, Zhao YC et al. HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression. Oncol. Rep. 30(5), 2495–2501 (2013).
  Medline CASGoogle Scholar
• 58 Paranjpe A, Zhang RW, Ali-Osman F et al. Disulfiram is a direct and potent inhibitor of human O⁶-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis 35(3), 692–702 (2014). • An excellent investigation demonstrated that alcohol aversion drug, disulfiram, is a direct and potent inhibitor of resistant MGMT protein.
  Medline CASGoogle Scholar
• 59 Zhao YC, Xiao Z, Chen WN et al. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O⁶-methylguanine-DNA methyltransferase expression. Mol. Med. Rep. 12(2), 2313–2322 (2015).
  Medline CASGoogle Scholar
• 60 Grogan PT, Sarkaria JN, Timmermann BN et al. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Invest. New Drugs 32(4), 604–617 (2014).
  Medline CASGoogle Scholar
• 61 Paranjpe A, Bailey NI, Konduri S et al. New insights into estrogenic regulation of O⁶-methylguanine DNA-methyltransferase (MGMT) in human breast cancer cells: co-degradation of ER-α and MGMT proteins by fulvestrant or O⁶-benzylguanine indicates fresh avenues for therapy. J. Biomed. Res. 30(5), 393–410 (2016).
  MedlineGoogle Scholar
• 62 Reinhard J, Eichhorn U, Wiessler M et al. Inactivation of O⁶-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors. Int. J. Cancer. 93(3), 373–379 (2001).
  Medline CASGoogle Scholar
• 63 Dolan ME, Stine L, Mitchell RB et al. Modulation of mammalian O⁶-alkylguanine-DNA alkyltransferase in vivo by O⁶-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun. 2(11), 371–377 (1990).
  Medline CASGoogle Scholar
• 64 Friedman HS, Dolan ME, Moschel RC et al. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma-multiforme. J. Natl Cancer Inst. 84(24), 1926–1931 (1992).
  Medline CASGoogle Scholar
• 65 Felker GM, Friedman HS, Dolan ME et al. Treatment of subcutaneous and intracranial brain-tumor xenografts with O⁶-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother. Pharmacol. 32(6), 471–476 (1993).
  Medline CASGoogle Scholar
• 66 Kokkinakis DM, Ahmed MM, Chendil D et al. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O⁶-methylguanine-DNA methyltransferase with O⁶-benzylguanine or O⁶-benzyl-2′-deoxyguanosine. Clin. Cancer Res. 9(10), 3801–3807 (2003).
  Medline CASGoogle Scholar
• 67 Kurpad SN, Dolan ME, McLendon RE et al. Intraarterial O⁶-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother. Pharmacol. 39(4), 307–316 (1997).
  Medline CASGoogle Scholar
• 68 Wedge SR, Newlands ES. O⁶-Benzylguanine enhances the sensitivity of a glioma xenograft with low O⁶-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br. J. Cancer. 73(9), 1049–1052 (1996).
  Medline CASGoogle Scholar
• 69 Keir ST, Dolan ME, Pegg AE et al. O⁶-benzylguanine-mediated enhancement of nitrosourea activity in Mer⁻ central nervous system tumor xenografts – implications for clinical trials. Cancer Chemother. Pharmacol. 45(6), 437–440 (2000).
  Medline CASGoogle Scholar
• 70 Middleton MR, Kelly J, Thatcher N et al. O⁶-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int. J. Cancer 85(2), 248–252 (2000).
  Medline CASGoogle Scholar
• 71 Middleton MR, Thatcher N, McMurry TBH et al. Effect of O⁶-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model. Int. J. Cancer. 100(5), 615–617 (2002).
  Medline CASGoogle Scholar
• 72 Clemons M, Kelly J, Watson AJ et al. O⁶-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. Br. J. Cancer. 93(10), 1152–1156 (2005).
  Medline CASGoogle Scholar
• 73 Schilsky RL, Dolan ME, Bertucci D et al. Phase I clinical and pharmacological study of O⁶-benzylguanine followed by carmustine in patients with advanced cancer. Clin. Cancer Res. 6(8), 3025–3031 (2000).
  Medline CASGoogle Scholar
• 74 Dolan ME, Posner M, Karrison T et al. Determination of the optimal modulatory dose of O⁶-benzylguanine in patients with surgically resectable tumors. Clin. Cancer Res. 8(8), 2519–2523 (2002).
  Medline CASGoogle Scholar
• 75 Quinn JA, Desjardins A, Weingart J et al. Phase I trial of temozolomide plus O⁶-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol. 23(28), 7178–7187 (2005).
  Medline CASGoogle Scholar
• 76 Friedman HS, Pluda J, Quinn JA et al. Phase I trial of carmustine plus O⁶-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol. 18(20), 3522–3528 (2000).
  Medline CASGoogle Scholar
• 77 Adams DM, Zhou T, Berg SL et al. Phase I trial of O⁶-benzylguanine and BCNU in children with CNS tumors: a children's oncology group study. Pediatr. Blood Cancer 50(3), 549–553 (2008).
  MedlineGoogle Scholar
• 78 Ranson M, Middleton MR, Bridgewater J et al. Lomeguatrib, a potent inhibitor of O⁶-alkylguanine-DNA-alkyltransferase: Phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 12(5), 1577–1584 (2006).
  Medline CASGoogle Scholar
• 79 Kefford RF, Thomas NPB, Corrie PG et al. A Phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. Br. J. Cancer 100(8), 1245–1249 (2009).
  Medline CASGoogle Scholar
• 80 Tawbi HA, Villaruz L, Tarhini A et al. Inhibition of DNA repair with MGMT pseudosubstrates: Phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br. J. Cancer 105(6), 773–777 (2011).
  Medline CASGoogle Scholar
• 81 Tserng KY, Ingalls ST, Boczko EM et al. Pharmacokinetics of O⁶-benzylguanine (NSC637037) and its metabolite, 8-oxo-O⁶-benzylguanine. J. Clin. Pharmacol. 43(8), 881–893 (2003).
  Medline CASGoogle Scholar
• 82 Long L, Dolan ME. Role of cytochrome P450 isoenzymes in metabolism of O⁶-benzylguanine: implications for dacarbazine activation. Clin. Cancer Res. 7(12), 4239–4244 (2001).
  Medline CASGoogle Scholar
• 83 Long L, Moschel RC, Dolan ME. Debenzylation of O⁶-benzyl-8-oxoguanine in human liver: implications for O⁶-benzylguanine metabolism. Biochem. Pharmacol. 61(6), 721–726 (2001).
  Medline CASGoogle Scholar
• 84 Quinn JA, Pluda J, Dolan ME et al. Phase II trial of carmustine plus O⁶-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol. 20(9), 2277–2283 (2002).
  Medline CASGoogle Scholar
• 85 Gajewski TF, Sosman J, Gerson SL et al. Phase II trial of the O⁶-alkylguanine DNA alkyltransferase inhibitor O⁶-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin. Cancer Res. 11(21), 7861–7865 (2005).
  Medline CASGoogle Scholar
• 86 Ryan CW, Dolan ME, Brockstein BB et al. A Phase II trial of O⁶-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother. Pharmacol. 58(5), 634–639 (2006).
  Medline CASGoogle Scholar
• 87 Batts ED, Maisel C, Kane D et al. O⁶-benzylguanine and BCNU in multiple myeloma: a Phase II trial. Cancer Chemother. Pharmacol. 60(3), 415–421 (2007).
  Medline CASGoogle Scholar
• 88 Quinn JA, Jiang SX, Reardon DA et al. Phase II trial of temozolomide plus O⁶-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J. Clin. Oncol. 27(8), 1262–1267 (2009).
  Medline CASGoogle Scholar
• 89 Warren KE, Gururangan S, Geyer JR et al. A Phase II study of O⁶-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J. Neurooncol. 106(3), 643–649 (2012).
  Medline CASGoogle Scholar
• 90 Ranson M, Hersey P, Thompson D et al. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J. Clin. Oncol. 25(18), 2540–2545 (2007).
  Medline CASGoogle Scholar
• 91 Khan OA, Ranson M, Michael M et al. A Phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br. J. Cancer 98(10), 1614–1618 (2008).
  Medline CASGoogle Scholar
• 92 Middleton MR, Margison GP. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol. 4(1), 37–44 (2003).
  Medline CASGoogle Scholar
• 93 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011).
  Medline CASGoogle Scholar
• 94 Reinhard J, Hull WE, von der Lieth CW et al. Monosaccharide-linked inhibitors of O⁶-methylguanine-DNA methyltransferase (MGMT): synthesis, molecular modeling, and structure–activity relationships. J. Med. Chem. 44(24), 4050–4061 (2001).
  Medline CASGoogle Scholar
• 95 Kaina B, Muhlhausen U, Piee-Staffa A et al. Inhibition of O⁶-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. J. Pharmacol. Exp. Ther. 311(2), 585–593 (2004).
  Medline CASGoogle Scholar
• 96 Walther R, Rautio J, Zelikin AN. Prodrugs in medicinal chemistry and enzyme prodrug therapies. Adv. Drug Deliv. Rev. 118, 65–77 (2017).
  Medline CASGoogle Scholar
• 97 Dolan ME, Roy SK, Garbiras BJ et al. O⁶-alkylguanine-DNA alkyltransferase inactivation by ester prodrugs of O⁶-benzylguanine derivatives and their rate of hydrolysis by cellular esterases. Biochem. Pharmacol. 55(10), 1701–1709 (1998).
  Medline CASGoogle Scholar
• 98 Ladino CA, Chari RVJ, Bourret LA et al. Folate-maytansinoids: target-selective drugs of low molecular weight. Int. J. Cancer 73(6), 859–864 (1997).
  Medline CASGoogle Scholar
• 99 Nelson ME, Loktionova NA, Pegg AE et al. 2-Amino-O⁴-benzylpteridine derivatives: potent inactivators of O⁶-alkylguanine-DNA alkyltransferase. J. Med. Chem. 47(15), 3887–3891 (2004).
  Medline CASGoogle Scholar
• 100 Javanmard S, Loktionova NA, Fang Q et al. Inactivation of O⁶-alkylguanine-DNA alkyltransferase by folate esters of O⁶-benzyl-2′-deoxyguanosine and of O⁶-[4-(hydroxymethyl)benzyl]guanine. J. Med. Chem. 50(21), 5193–5201 (2007).
  Medline CASGoogle Scholar
• 101 Tranoy-Opalinski I, Legigan T, Barat R et al. β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update. Eur. J. Med. Chem. 74, 302–313 (2014).
  Medline CASGoogle Scholar
• 102 Wei GP, Loktionova NA, Pegg AE et al. β-glucuronidase-cleavable prodrugs of O⁶-benzylguanine and O⁶-benzyl-2′-deoxyguanosine. J. Med. Chem. 48(1), 256–261 (2005).
  Medline CASGoogle Scholar
• 103 Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer. 11(6), 393–410 (2011).
  Medline CASGoogle Scholar
• 104 Zhu R, Liu MC, Luo MZ et al. 4-Nitrobenzyloxycarbonyl derivatives of O⁶-benzylguanine as hypoxia-activated prodrug inhibitors of O⁶-alkylguanine-dna alkyltransferase (AGT), which produces resistance to agents targeting the O⁶ position of DNA guanine. J. Med. Chem. 54(21), 7720–7728 (2011). •• A typical example of hypoxia-activated MGMT inhibitors with tumor targeting ability.
  Medline CASGoogle Scholar
• 105 Zhu R, Seow HA, Baumann RP et al. Design of a hypoxia-activated prodrug inhibitor of O⁶-alkylguanine-DNA alkyltransferase. Bioorg. Med. Chem. Lett. 22(19), 6242–6247 (2012).
  Medline CASGoogle Scholar
• 106 Penketh PG, Shyam K, Baumann RP et al. A strategy for selective O⁶-alkylguanine-DNA alkyltransferase depletion under hypoxic conditions. Chem. Biol. Drug. Des. 80(2), 279–290 (2012).
  Medline CASGoogle Scholar
• 107 Zhu R, Baumann RP, Penketh PG et al. Hypoxia-selective O⁶-alkylguanine-DNA alkyltransferase inhibitors: design, synthesis, and evaluation of 6-(benzyloxy)-2-(aryldiazenyl)-9H-purines as prodrugs of O⁶-benzylguanine. J. Med. Chem. 56(3), 1355–1359 (2013).
  Medline CASGoogle Scholar
• 108 Guerin C, Olivi A, Weingart JD et al. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest. New Drugs 22(1), 27–37 (2004).
  Medline CASGoogle Scholar
• 109 Tseng YY, Kau YC, Liu SJ. Advanced interstitial chemotherapy for treating malignant glioma. Expert Opin. Drug Del. 13(11), 1533–1544 (2016).
  Medline CASGoogle Scholar
• 110 Weingart J, Grossman SA, Carson KA et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O⁶-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J. Clin. Oncol. 25(4), 399–404 (2007).
  Medline CASGoogle Scholar
• 111 Quinn JA, Jiang SX, Carter J et al. Phase II trial of Gliadel plus O⁶-benzylguanine in adults with recurrent glioblastoma multiforme. Clin. Cancer Res. 15(3), 1064–1068 (2009).
  Medline CASGoogle Scholar
• 112 Apisarnthanarax N, Wood GS, Stevens SR et al. Phase I clinical trial of O⁶-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, Mycosis Fungoides Type. Arch. Dermatol. 148(5), 613–620 (2012).
  Medline CASGoogle Scholar
• 113 Tacastacas JD, Chan DV, Carlson S et al. Evaluation of O⁶-benzylguanine-potentiated topical carmustine for Mycosis Fungoides: a Phase I–II clinical trial. JAMA Dermatol. 153(5), 413–420 (2017).
  MedlineGoogle Scholar
• 114 Koch D, Hundsberger T, Boor S et al. Local intracerebral administration of O⁶-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma. J. Neurooncol. 82(1), 85–89 (2007).
  Medline CASGoogle Scholar
• 115 Loktionova NA, Xu-Welliver M, Crone TM et al. Protection of CHO cells by mutant forms of O⁶-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O⁶-benzylguanine or O⁶-benzyl-8-oxoguanine. Biochem. Pharmacol. 58(2), 237–244 (1999).
  Medline CASGoogle Scholar
• 116 Davis BM, Reese JS, Koc ON et al. Selection for G156A O⁶-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O⁶-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 57(22), 5093–5099 (1997).
  Medline CASGoogle Scholar
• 117 Davis BM, Koc ON, Gerson SL. Limiting numbers of G156A O⁶-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood 95(10), 3078–3084 (2000).
  Medline CASGoogle Scholar
• 118 Ragg S, Xu-Welliver M, Bailey J et al. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res. 60(18), 5187–5195 (2000).
  Medline CASGoogle Scholar
• 119 Jansen M, Sorg UR, Ragg S et al. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT^P140K into hematopoietic stem cells. Cancer Gene Ther. 9(9), 737–746 (2002).
  Medline CASGoogle Scholar
• 120 Ball CR, Pilz IH, Schmidt M et al. Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression. Blood 110(6), 1779–1787 (2007).
  Medline CASGoogle Scholar
• 121 Crone TM, Goodtzova K, Edara S et al. Mutations in human O⁶-alkylguanine-DNA alkyltransferase imparting resistance to O⁶-benzylguanine. Cancer Res. 54(23), 6221–6227 (1994).
  Medline CASGoogle Scholar
• 122 Xu-Welliver M, Kanugula S, Pegg AE. Isolation of human O⁶-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O⁶-benzylguanine. Cancer Res. 58(9), 1936–1945 (1998).
  Medline CASGoogle Scholar
• 123 Woolford LB, Southgate TD, Margison GP et al. The P140K mutant of human O⁶-methylguanine-DNA-methyttransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O⁶-(4-bromothenyl)guanine. J. Gene Med. 8(1), 29–34 (2006).
  Medline CASGoogle Scholar
• 124 Neff T, Beard BC, Peterson LJ et al. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 105(3), 997–1002 (2005).
  Medline CASGoogle Scholar
• 125 Beard BC, Trobridge GD, Ironside C et al. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J. Clin. Invest. 120(7), 2345–2354 (2010).
  Medline CASGoogle Scholar
• 126 Maier P, Spier I, Laufs S et al. Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O⁶-methylguanine-DNA methyltransferase(P140K). Gene Ther. 17(3), 389–399 (2010).
  Medline CASGoogle Scholar
• 127 Maier P, Heckmann D, Spier I et al. F2A sequence linking MGMT^P140K and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells. Cancer Gene Ther. 19(11), 802–810 (2012).
  Medline CASGoogle Scholar
• 128 Koc ON, Reese JS, Davis BM et al. Delta MGMT-transduced bone marrow infusion increases tolerance to O⁶-benzylguanine and 1,3-bis(2-chloroethy1)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts. Hum Gene Ther. 10(6), 1021–1030 (1999).
  Medline CASGoogle Scholar